PHR1287

Supelco

Glyburide (Glibenclamide)

Pharmaceutical Secondary Standard; Certified Reference Material

Synonym(s):
Glybenclamide, Glyburide, N-p-[2-(5-Chloro-2-methoxybenzamido)ethyl]benzenesulfonyl-N′-cyclohexylurea, 5-Chloro-N-[4-(cyclohexylureidosulfonyl)phenethyl]-2-methoxybenzamide
Empirical Formula (Hill Notation):
C23H28ClN3O5S
CAS Number:
Molecular Weight:
494.00
EC Number:
MDL number:
PubChem Substance ID:
NACRES:
NA.24
Pricing and availability is not currently available.

Quality Level

grade

certified reference material
pharmaceutical secondary standard

form

neat

CofA

current certificate can be downloaded

application(s)

HPLC: suitable
gas chromatography (GC): suitable

Featured Industry

Pharmaceutical (small molecule)

format

neat

pharmacopeia traceability

traceable to BP 175
traceable to PhEur G0325000
traceable to USP 1295505

SMILES string

COc1ccc(Cl)cc1C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)NC3CCCCC3

InChI

1S/C23H28ClN3O5S/c1-32-21-12-9-17(24)15-20(21)22(28)25-14-13-16-7-10-19(11-8-16)33(30,31)27-23(29)26-18-5-3-2-4-6-18/h7-12,15,18H,2-6,13-14H2,1H3,(H,25,28)(H2,26,27,29)

InChI key

ZNNLBTZKUZBEKO-UHFFFAOYSA-N

Gene Information

human ... ABCC8(6833), KCNJ11(3767)

Looking for similar products? Visit Product Comparison Guide

General description

Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.
Glyburide (Glibenclamide) is a potent second-generation sulfonylurea widely utilized as an anti-diabetic drug, typically against type 2 diabetes. Its mode of action majorly involves the stimulation of endogenous insulin release from beta cells of pancreas.

Application

These Secondary Standards are qualified as Certified Reference Materials. These are suitable for use in several analytical applications including but not limited to pharma release testing, pharma method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements.
Glyburide (Glibenclamide) may be used as a pharmaceutical reference standard for the determination of the analyte in pharmaceutical formulations and plasma samples by chromatography techniques.

Analysis Note

These secondary standards offer multi-traceability to the USP, EP (PhEur) and BP primary standards, where they are available.

Other Notes

This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis.

Footnote

To see an example of a Certificate of Analysis for this material enter LRAC3255 in the slot below. This is an example certificate only and may not be the lot that you receive.

RIDADR

NONH for all modes of transport

WGK Germany

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificate of Analysis
Certificate of Origin
Application of liquid chromatography atmospheric pressure chemical ionization tandem mass spectrometry in the quantitative analysis of glyburide (glibenclamide) in human plasma
Ramos L, et al.
Rapid Communications in Mass Spectrometry, 13(24), 2439-2443 (1999)
Simultaneous assay of metformin and glibenclamide in human plasma based on extraction-less sample preparation procedure and LC/(APCI) MS
Georgita C, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 854(1-2), 211-218 (2007)
Detection of phenformin and glyburide illegally mixed into traditional Chinese medicine antidiabetic preparations by the liquid chromatography-mass spectrometry method [J]
Yu D, et al.
Journal of Shenyang Pharmaceutical University, 1 (2005)
A validated high-performance liquid chromatographic method for the determination of glibenclamide in human plasma and its application to pharmacokinetic studies
Niopas I, et al.
Journal of Pharmaceutical and Biomedical Analysis, 28(3-4), 653-657 (2002)
Alfredo Juárez-Saldivar et al.
International journal of molecular sciences, 21(12) (2020-06-21)
Chagas disease, caused by Trypanosoma cruzi (T. cruzi), affects nearly eight million people worldwide. There are currently only limited treatment options, which cause several side effects and have drug resistance. Thus, there is a great need for a novel, improved...

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.